can make a major contribution to sustaining and enhancing the local R&D ecosystem and supporting our collective future by ensuring a steady supply of young people with advanced training and education,” said Christopher Viehbacher, Chief Executive Officer, Sanofi. “By supporting a vibrant life sciences community, we are also laying the foundation for the research that will drive future innovations for patients.”
“Increased access to STEM education is essential to Massachusetts’ future economic competitiveness, including our strength as a global leader in the life sciences,” said Governor Deval Patrick. “I thank Sanofi and Genzyme for the generous contribution to our UMass Boston students and efforts to ensure that our state’s STEM workforce pipeline remains strong.”
The gift from Sanofi and Genzyme marks the third significant philanthropic gift this year supporting CSM student success programs. Earlier this year, San Francisco-based software giant Oracle gave $300,000 to support student success efforts in CSM, and Ralph and Janice James pledged $1 million to support student success efforts campus-wide.
With Sanofi and Genzyme’s support, CSM Dean Andrew Grosovsky plans to expand the student success program and develop new opportunities for undergraduate and graduate research.
“We couldn’t be more excited and grateful for this partnership with Sanofi and Genzyme,” said Dean Grosovsky. “CSM has experienced dramatic increases in enrollment and is a minority-majority college with large numbers of first-generation and low-income students. Since the retention and academic performance has been so strong, we are on track to greatly increase the number and diversity of STEM graduates. These graduates will be competitive for admission to graduate or professional schools, or to enter the STEM workforce.”
About UMass Boston
Recognized for its reputation for innovative research addressing complex issues, the University of Massa
Page: 1 2 3 Related biology technology :1
Copyright©2012 Vocus, Inc.
All rights reserved
. Freeslate’s Biologics Formulation System Selected by Sanofi Pasteur to Improve Efficiency of Formulation Development2
. Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security3
. U.S. FDA Grants Fast-Track Designation to Sanofi Pasteur and KaloBios Novel Biologic Candidate for Pseudomonas aeruginosa4
. Sanofi Oncology and Colon Cancer Coalition Join Forces to Raise Awareness of Colorectal Cancer5
. A Look Inside, Factors of Health - Research Report on Novogen Limited, Sanofi SA, ISIS Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc.6
. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody7
. Sanofi Signs Agreement for Type 1 Diabetes Research with Boston Academic Teaching Hospital8
. Collaboration between Sanofi and Joslin Diabetes Center to focus on new drugs for diabetes9
. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet10
. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer11
. PharmaVentures Client Sanofi Wins Scrip Outsourcing Deal of the Year Award